• HCQ has become highly politicised in US but India uses it widely: WH
    New Delhi, July 8 (PTI): The use of hydroxychloroquine to treat coronavirus patients has become highly politicized in the United States but it is used widely in India, a top White House official has said, asserting latest research showed the malaria drug is highly effective in early stages of COVID-19.      "It's the politicisation of this medicine by the mainstream media and portions of the medical community that somehow made this a battle between Preside
  • WHO will decide on its hydroxychloroquine trial suspension in 24 hours
    Reuters The World Health Organization (WHO) should have enough information in 24 hours to decide whether to continue suspending its trials of hydroxychloroquine for use against the new coronavirus, its chief scientist Soumya Swaminathan said on Monday.   U.S. President Donald Trump has been one of those promoting the anti-malaria drug to help combat the COVID-19 disease, despite medical warnings about associated risks.
  • France, Italy, Belgium act to stop use of hydroxychloroquine for COVID-19 on safety fears
    PARIS, May 27  (Reuters):  France, Italy and Belgium acted to halt the use of hydroxychloroquine to treat patients suffering from COVID-19, the illness caused by the new coronavirus, amid questions about the safety of the generic anti-malaria drug. France on Wednesday cancelled a decree allowing hospital doctors to dispense the medicine, while the Italian Medicine Agency (AIFA) suspended authorization to use hydroxychloroquine for COVID-19 outside clinical trials. B
  • WHO says hydroxychloroquine safety findings expected by mid-June
    ZURICH, May 26 (Reuters): The World Health Organization (WHO) said on Tuesday that a safety team would review data on hydroxychloroquine by next month, a day after officials cited safety concerns that prompted them to suspend use of the malaria drug in a global trial in COVID-19 patients.   The WHO called time on using the drug in its multi-country trial, called Solidarity, after a study published in British medical journal The Lancet found patients randomised to get hy
  • India to continue using HCQ as prophylaxis for COVID: ICMR
    New Delhi, May 26 (IANS) The Indian Council of Medical Research on Tuesday said it will continue using hydroxychloroquine (HCQ) medicine as prophylaxis for COVID-19 disease.   Speaking at a press conference, Dr Balram Bhargava, Director General (DG) of the ICMR, told the media that the Council found the drug very effective and having less side effects for prophylaxis consumption.   The clinical trial of the HCQ on COVID-19 patients was suspended by the World Healt